| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 55 | 2021 | 961 | 7.170 |
Why?
|
| Antihypertensive Agents | 37 | 2021 | 352 | 4.940 |
Why?
|
| Dementia | 30 | 2020 | 253 | 4.700 |
Why?
|
| Blood Pressure | 30 | 2021 | 846 | 3.500 |
Why?
|
| Cognition | 40 | 2020 | 556 | 3.360 |
Why?
|
| Aged | 170 | 2021 | 10308 | 2.760 |
Why?
|
| Diabetes Mellitus, Type 2 | 38 | 2018 | 1428 | 2.600 |
Why?
|
| Randomized Controlled Trials as Topic | 18 | 2020 | 510 | 2.550 |
Why?
|
| Cognition Disorders | 23 | 2018 | 385 | 2.370 |
Why?
|
| Brain | 30 | 2019 | 948 | 2.320 |
Why?
|
| Blood Pressure Determination | 10 | 2019 | 100 | 2.280 |
Why?
|
| Humans | 205 | 2021 | 32082 | 2.000 |
Why?
|
| Aged, 80 and over | 85 | 2020 | 3990 | 1.780 |
Why?
|
| Female | 166 | 2021 | 19999 | 1.750 |
Why?
|
| Cardiovascular Diseases | 29 | 2021 | 1128 | 1.700 |
Why?
|
| Male | 151 | 2021 | 19202 | 1.670 |
Why?
|
| Exercise | 10 | 2020 | 672 | 1.660 |
Why?
|
| Mobility Limitation | 14 | 2020 | 219 | 1.650 |
Why?
|
| Magnetic Resonance Imaging | 34 | 2019 | 1325 | 1.600 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 8 | 2019 | 145 | 1.550 |
Why?
|
| Activities of Daily Living | 17 | 2019 | 257 | 1.530 |
Why?
|
| Disabled Persons | 16 | 2018 | 105 | 1.490 |
Why?
|
| Exercise Therapy | 10 | 2021 | 270 | 1.380 |
Why?
|
| Aspirin | 7 | 2020 | 63 | 1.370 |
Why?
|
| Geriatric Assessment | 19 | 2020 | 390 | 1.330 |
Why?
|
| Hypercholesterolemia | 6 | 2017 | 70 | 1.280 |
Why?
|
| Alzheimer Disease | 10 | 2020 | 327 | 1.250 |
Why?
|
| Life Style | 11 | 2020 | 408 | 1.220 |
Why?
|
| Osteoarthritis, Knee | 9 | 2021 | 90 | 1.200 |
Why?
|
| Aging | 20 | 2017 | 943 | 1.130 |
Why?
|
| Geriatrics | 4 | 2017 | 85 | 1.100 |
Why?
|
| Ginkgo biloba | 10 | 2017 | 19 | 1.060 |
Why?
|
| Pravastatin | 5 | 2017 | 13 | 1.020 |
Why?
|
| Risk Factors | 47 | 2020 | 3880 | 0.990 |
Why?
|
| Middle Aged | 81 | 2021 | 11834 | 0.960 |
Why?
|
| Frail Elderly | 5 | 2016 | 68 | 0.940 |
Why?
|
| Plant Extracts | 8 | 2019 | 61 | 0.850 |
Why?
|
| Anticholesteremic Agents | 4 | 2013 | 39 | 0.830 |
Why?
|
| American Heart Association | 7 | 2019 | 87 | 0.820 |
Why?
|
| Neuropsychological Tests | 21 | 2019 | 371 | 0.800 |
Why?
|
| Patient Compliance | 7 | 2017 | 225 | 0.800 |
Why?
|
| United States | 32 | 2020 | 3975 | 0.770 |
Why?
|
| Motor Activity | 7 | 2013 | 324 | 0.750 |
Why?
|
| Accidental Falls | 5 | 2019 | 221 | 0.740 |
Why?
|
| Treatment Outcome | 33 | 2021 | 3304 | 0.730 |
Why?
|
| Practice Guidelines as Topic | 6 | 2019 | 407 | 0.720 |
Why?
|
| Cardiology | 5 | 2018 | 99 | 0.690 |
Why?
|
| Advance Care Planning | 1 | 2019 | 15 | 0.690 |
Why?
|
| Disease Management | 5 | 2017 | 126 | 0.690 |
Why?
|
| Documentation | 1 | 2019 | 46 | 0.670 |
Why?
|
| Hypoglycemic Agents | 6 | 2016 | 181 | 0.660 |
Why?
|
| Disability Evaluation | 14 | 2017 | 240 | 0.660 |
Why?
|
| Health Status | 12 | 2016 | 400 | 0.660 |
Why?
|
| Food Services | 3 | 2015 | 20 | 0.640 |
Why?
|
| Double-Blind Method | 19 | 2020 | 525 | 0.610 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 72 | 0.600 |
Why?
|
| Retirement | 1 | 2017 | 13 | 0.600 |
Why?
|
| Decision Making | 1 | 2019 | 194 | 0.590 |
Why?
|
| Phytotherapy | 5 | 2008 | 38 | 0.580 |
Why?
|
| Diabetic Angiopathies | 8 | 2015 | 143 | 0.580 |
Why?
|
| Myocardial Infarction | 7 | 2016 | 473 | 0.570 |
Why?
|
| Single-Blind Method | 12 | 2017 | 203 | 0.570 |
Why?
|
| Cross-Sectional Studies | 24 | 2020 | 1542 | 0.570 |
Why?
|
| African Americans | 13 | 2018 | 1424 | 0.560 |
Why?
|
| Memory | 9 | 2019 | 190 | 0.560 |
Why?
|
| Internal Medicine | 1 | 2017 | 54 | 0.560 |
Why?
|
| Vitamins | 2 | 2015 | 68 | 0.560 |
Why?
|
| Follow-Up Studies | 26 | 2021 | 2263 | 0.550 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 8 | 2014 | 135 | 0.540 |
Why?
|
| Obesity | 10 | 2015 | 1176 | 0.540 |
Why?
|
| Chronic Disease | 5 | 2019 | 406 | 0.530 |
Why?
|
| Cohort Studies | 24 | 2019 | 1816 | 0.520 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2014 | 84 | 0.520 |
Why?
|
| Homebound Persons | 1 | 2015 | 9 | 0.510 |
Why?
|
| Cholecalciferol | 1 | 2015 | 21 | 0.510 |
Why?
|
| Depression | 8 | 2016 | 445 | 0.510 |
Why?
|
| Adult | 31 | 2021 | 9375 | 0.500 |
Why?
|
| Dietary Supplements | 3 | 2015 | 185 | 0.490 |
Why?
|
| Walking | 11 | 2015 | 209 | 0.490 |
Why?
|
| Hypotension | 1 | 2015 | 47 | 0.490 |
Why?
|
| Body Mass Index | 13 | 2016 | 923 | 0.490 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2020 | 291 | 0.480 |
Why?
|
| Health Education | 6 | 2017 | 163 | 0.480 |
Why?
|
| Hospitalization | 7 | 2019 | 468 | 0.480 |
Why?
|
| Patient Readmission | 1 | 2015 | 126 | 0.470 |
Why?
|
| Pilot Projects | 8 | 2021 | 547 | 0.470 |
Why?
|
| Lipids | 2 | 2014 | 232 | 0.470 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 194 | 0.460 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2018 | 83 | 0.460 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2013 | 3 | 0.450 |
Why?
|
| Chlorthalidone | 7 | 2017 | 13 | 0.450 |
Why?
|
| Calcium Channel Blockers | 7 | 2014 | 48 | 0.450 |
Why?
|
| Cerebrovascular Disorders | 2 | 2013 | 52 | 0.450 |
Why?
|
| Organ Size | 11 | 2019 | 218 | 0.450 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2020 | 201 | 0.450 |
Why?
|
| Models, Educational | 1 | 2013 | 20 | 0.440 |
Why?
|
| Diuretics | 5 | 2013 | 26 | 0.440 |
Why?
|
| Internship and Residency | 1 | 2017 | 311 | 0.440 |
Why?
|
| Health Promotion | 3 | 2015 | 258 | 0.430 |
Why?
|
| Cause of Death | 6 | 2020 | 236 | 0.420 |
Why?
|
| Prospective Studies | 17 | 2020 | 2282 | 0.400 |
Why?
|
| Diabetes Mellitus | 4 | 2017 | 412 | 0.400 |
Why?
|
| Blood Glucose | 9 | 2016 | 494 | 0.400 |
Why?
|
| Heart Failure | 3 | 2016 | 639 | 0.390 |
Why?
|
| Coronary Artery Disease | 4 | 2015 | 401 | 0.380 |
Why?
|
| Age Factors | 17 | 2020 | 1187 | 0.380 |
Why?
|
| Health Services for the Aged | 3 | 2019 | 25 | 0.370 |
Why?
|
| Risk Assessment | 10 | 2020 | 1427 | 0.370 |
Why?
|
| Longitudinal Studies | 15 | 2019 | 770 | 0.370 |
Why?
|
| Health Status Indicators | 6 | 2020 | 73 | 0.360 |
Why?
|
| Incidence | 10 | 2019 | 1199 | 0.350 |
Why?
|
| Diabetes Complications | 4 | 2018 | 177 | 0.350 |
Why?
|
| Research Design | 8 | 2020 | 315 | 0.350 |
Why?
|
| Australia | 7 | 2020 | 72 | 0.350 |
Why?
|
| Amlodipine | 6 | 2017 | 13 | 0.340 |
Why?
|
| Prevalence | 11 | 2020 | 989 | 0.330 |
Why?
|
| Lisinopril | 6 | 2017 | 26 | 0.330 |
Why?
|
| Life Expectancy | 2 | 1999 | 16 | 0.320 |
Why?
|
| Weight Loss | 6 | 2015 | 480 | 0.320 |
Why?
|
| Muscle Strength | 3 | 2013 | 160 | 0.310 |
Why?
|
| Advisory Committees | 2 | 2017 | 30 | 0.300 |
Why?
|
| Personal Satisfaction | 2 | 2008 | 28 | 0.300 |
Why?
|
| Chondroitin | 1 | 2007 | 2 | 0.300 |
Why?
|
| Glucosamine | 1 | 2007 | 7 | 0.290 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2007 | 13 | 0.290 |
Why?
|
| Mortality | 3 | 2018 | 125 | 0.290 |
Why?
|
| Patient Care Planning | 2 | 2020 | 58 | 0.280 |
Why?
|
| European Continental Ancestry Group | 7 | 2018 | 1165 | 0.280 |
Why?
|
| Diet, Reducing | 3 | 2015 | 106 | 0.280 |
Why?
|
| Vascular Diseases | 3 | 2015 | 66 | 0.280 |
Why?
|
| Deglutition | 3 | 2011 | 29 | 0.280 |
Why?
|
| Executive Function | 2 | 2017 | 57 | 0.280 |
Why?
|
| Respiratory Aspiration | 3 | 2011 | 21 | 0.280 |
Why?
|
| Comorbidity | 10 | 2018 | 566 | 0.260 |
Why?
|
| Anxiety | 4 | 2015 | 191 | 0.250 |
Why?
|
| Albuminuria | 5 | 2020 | 181 | 0.250 |
Why?
|
| Amyloid | 2 | 2017 | 15 | 0.250 |
Why?
|
| Anxiety Disorders | 3 | 2012 | 77 | 0.250 |
Why?
|
| Glomerular Filtration Rate | 8 | 2020 | 308 | 0.250 |
Why?
|
| Homes for the Aged | 2 | 2003 | 20 | 0.250 |
Why?
|
| Hypoglycemia | 3 | 2014 | 45 | 0.240 |
Why?
|
| Nursing Homes | 2 | 2003 | 42 | 0.240 |
Why?
|
| Carbamates | 1 | 2004 | 15 | 0.240 |
Why?
|
| Metformin | 1 | 2004 | 22 | 0.240 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 753 | 0.240 |
Why?
|
| Analysis of Variance | 6 | 2013 | 462 | 0.240 |
Why?
|
| Administration, Oral | 6 | 2018 | 187 | 0.240 |
Why?
|
| Medication Adherence | 2 | 2016 | 161 | 0.240 |
Why?
|
| Patient Selection | 5 | 2020 | 276 | 0.240 |
Why?
|
| Severity of Illness Index | 11 | 2017 | 881 | 0.240 |
Why?
|
| Multicenter Studies as Topic | 3 | 2020 | 105 | 0.240 |
Why?
|
| Diabetic Nephropathies | 3 | 2015 | 224 | 0.230 |
Why?
|
| Genome-Wide Association Study | 3 | 2016 | 547 | 0.230 |
Why?
|
| Independent Living | 4 | 2018 | 100 | 0.230 |
Why?
|
| Clinical Competence | 3 | 2017 | 331 | 0.230 |
Why?
|
| Hemorrhage | 3 | 2018 | 100 | 0.230 |
Why?
|
| Piperidines | 1 | 2004 | 118 | 0.230 |
Why?
|
| Community Health Services | 2 | 2020 | 56 | 0.220 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2013 | 23 | 0.220 |
Why?
|
| Hip Fractures | 3 | 2017 | 31 | 0.220 |
Why?
|
| Institutionalization | 1 | 2003 | 2 | 0.220 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 184 | 0.210 |
Why?
|
| Linear Models | 9 | 2017 | 448 | 0.210 |
Why?
|
| Overweight | 3 | 2014 | 280 | 0.210 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2014 | 132 | 0.210 |
Why?
|
| Biostatistics | 1 | 2012 | 7 | 0.210 |
Why?
|
| Time Factors | 11 | 2020 | 2145 | 0.210 |
Why?
|
| Goals | 2 | 2020 | 36 | 0.210 |
Why?
|
| Apolipoprotein E4 | 3 | 2019 | 63 | 0.210 |
Why?
|
| Death | 3 | 2017 | 49 | 0.210 |
Why?
|
| Antidepressive Agents | 3 | 2015 | 74 | 0.210 |
Why?
|
| Sexual Behavior | 1 | 2003 | 120 | 0.210 |
Why?
|
| Patient Transfer | 2 | 2020 | 43 | 0.210 |
Why?
|
| Quality-Adjusted Life Years | 2 | 1999 | 31 | 0.210 |
Why?
|
| Vitamin D | 2 | 2015 | 184 | 0.210 |
Why?
|
| Medicare | 2 | 2019 | 206 | 0.200 |
Why?
|
| Risk | 7 | 2020 | 321 | 0.200 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 317 | 0.190 |
Why?
|
| Sertraline | 2 | 2015 | 27 | 0.190 |
Why?
|
| Health Surveys | 4 | 2019 | 198 | 0.190 |
Why?
|
| Psychomotor Performance | 3 | 2011 | 98 | 0.190 |
Why?
|
| Electronic Health Records | 2 | 2020 | 164 | 0.190 |
Why?
|
| Gait | 3 | 2014 | 142 | 0.190 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2012 | 29 | 0.190 |
Why?
|
| Laryngoscopy | 2 | 2011 | 41 | 0.190 |
Why?
|
| Depressive Disorder | 2 | 2015 | 75 | 0.190 |
Why?
|
| Comprehensive Health Care | 1 | 2020 | 5 | 0.190 |
Why?
|
| Primary Health Care | 2 | 2017 | 227 | 0.180 |
Why?
|
| Women's Health | 3 | 2014 | 235 | 0.180 |
Why?
|
| Quality of Life | 8 | 2020 | 946 | 0.180 |
Why?
|
| Prognosis | 9 | 2019 | 1496 | 0.170 |
Why?
|
| Ideal Body Weight | 1 | 2009 | 7 | 0.170 |
Why?
|
| Staff Development | 1 | 2019 | 16 | 0.170 |
Why?
|
| Terminal Care | 1 | 2019 | 24 | 0.170 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2021 | 89 | 0.170 |
Why?
|
| Awareness | 1 | 2019 | 29 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2019 | 299 | 0.170 |
Why?
|
| Intelligence Tests | 3 | 2017 | 9 | 0.170 |
Why?
|
| Teaching | 1 | 2019 | 63 | 0.170 |
Why?
|
| Palliative Care | 1 | 2019 | 52 | 0.170 |
Why?
|
| Education, Medical | 1 | 2019 | 69 | 0.160 |
Why?
|
| Hospital Mortality | 1 | 2020 | 198 | 0.160 |
Why?
|
| Patient Participation | 1 | 2019 | 82 | 0.160 |
Why?
|
| Creatinine | 5 | 2020 | 196 | 0.160 |
Why?
|
| Faculty, Medical | 1 | 2019 | 76 | 0.160 |
Why?
|
| Artificial Intelligence | 2 | 2013 | 57 | 0.160 |
Why?
|
| Physical Fitness | 3 | 2012 | 131 | 0.160 |
Why?
|
| Coronary Disease | 4 | 2013 | 211 | 0.160 |
Why?
|
| Deglutition Disorders | 4 | 2011 | 51 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 185 | 0.160 |
Why?
|
| Caregivers | 1 | 2019 | 114 | 0.150 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 146 | 0.150 |
Why?
|
| North Carolina | 4 | 2020 | 1538 | 0.150 |
Why?
|
| Syncope | 1 | 2018 | 26 | 0.150 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2017 | 16 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 172 | 0.150 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 70 | 0.140 |
Why?
|
| Aniline Compounds | 2 | 2017 | 18 | 0.140 |
Why?
|
| Thiazoles | 2 | 2017 | 27 | 0.140 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2016 | 3 | 0.140 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2017 | 14 | 0.140 |
Why?
|
| Feasibility Studies | 2 | 2015 | 294 | 0.140 |
Why?
|
| Hypotension, Orthostatic | 1 | 2016 | 13 | 0.140 |
Why?
|
| Hand Strength | 2 | 2011 | 101 | 0.140 |
Why?
|
| Pelvic Bones | 1 | 2017 | 32 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 255 | 0.140 |
Why?
|
| Genotype | 4 | 2017 | 733 | 0.140 |
Why?
|
| Logistic Models | 7 | 2013 | 783 | 0.140 |
Why?
|
| Radiography | 4 | 2015 | 374 | 0.140 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 25 | 0.140 |
Why?
|
| Memory, Short-Term | 1 | 2017 | 60 | 0.140 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 22 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 69 | 0.140 |
Why?
|
| Aromatic-L-Amino-Acid Decarboxylases | 1 | 2016 | 4 | 0.140 |
Why?
|
| Apolipoproteins E | 1 | 2016 | 95 | 0.130 |
Why?
|
| Resistance Training | 2 | 2015 | 82 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 357 | 0.130 |
Why?
|
| Curriculum | 2 | 2019 | 213 | 0.130 |
Why?
|
| Educational Measurement | 2 | 2014 | 122 | 0.130 |
Why?
|
| Positron-Emission Tomography | 2 | 2017 | 163 | 0.130 |
Why?
|
| Sex Factors | 4 | 2019 | 667 | 0.130 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2014 | 140 | 0.130 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 47 | 0.130 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2015 | 37 | 0.120 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2014 | 199 | 0.120 |
Why?
|
| Hippocampus | 1 | 2016 | 170 | 0.120 |
Why?
|
| Spectrin | 1 | 2014 | 5 | 0.120 |
Why?
|
| Physicians | 1 | 2017 | 159 | 0.120 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2014 | 12 | 0.120 |
Why?
|
| Adiposity | 1 | 2016 | 198 | 0.120 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2014 | 53 | 0.120 |
Why?
|
| Algorithms | 4 | 2019 | 496 | 0.120 |
Why?
|
| Body Composition | 3 | 2012 | 396 | 0.120 |
Why?
|
| Motor Skills Disorders | 1 | 2014 | 7 | 0.120 |
Why?
|
| Brain Diseases | 1 | 2014 | 38 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 835 | 0.120 |
Why?
|
| Apolipoproteins | 1 | 2016 | 200 | 0.120 |
Why?
|
| Treatment Failure | 3 | 2018 | 162 | 0.120 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 65 | 0.120 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2013 | 1 | 0.110 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 251 | 0.110 |
Why?
|
| Atrophy | 4 | 2015 | 46 | 0.110 |
Why?
|
| Pneumonia | 1 | 2014 | 67 | 0.110 |
Why?
|
| Disease Progression | 4 | 2015 | 594 | 0.110 |
Why?
|
| Fractures, Bone | 1 | 2015 | 147 | 0.110 |
Why?
|
| Biological Transport | 1 | 2013 | 69 | 0.110 |
Why?
|
| Exercise Test | 4 | 2017 | 225 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2016 | 249 | 0.110 |
Why?
|
| Dopamine | 1 | 2016 | 232 | 0.110 |
Why?
|
| Stroke | 2 | 2017 | 584 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2013 | 14 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2014 | 225 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 2 | 2014 | 543 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2010 | 472 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 53 | 0.100 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 93 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2016 | 680 | 0.100 |
Why?
|
| Telephone | 1 | 2012 | 59 | 0.100 |
Why?
|
| Regression Analysis | 3 | 2016 | 292 | 0.100 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2015 | 97 | 0.100 |
Why?
|
| Gastrointestinal Transit | 1 | 2011 | 4 | 0.100 |
Why?
|
| Cholesterol | 1 | 2013 | 252 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2015 | 560 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 89 | 0.100 |
Why?
|
| Kidney Function Tests | 3 | 2017 | 107 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2019 | 483 | 0.100 |
Why?
|
| Leg | 2 | 2004 | 65 | 0.100 |
Why?
|
| Tongue | 1 | 2011 | 13 | 0.090 |
Why?
|
| Nootropic Agents | 1 | 2011 | 12 | 0.090 |
Why?
|
| Pain Measurement | 4 | 2013 | 349 | 0.090 |
Why?
|
| Smoking | 3 | 2017 | 528 | 0.090 |
Why?
|
| Esophageal Sphincter, Upper | 1 | 2010 | 3 | 0.090 |
Why?
|
| Pharynx | 1 | 2010 | 14 | 0.090 |
Why?
|
| Neoplasms | 2 | 2018 | 728 | 0.090 |
Why?
|
| Doxazosin | 1 | 2000 | 2 | 0.090 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2000 | 24 | 0.090 |
Why?
|
| Hypertensive Encephalopathy | 1 | 2010 | 1 | 0.090 |
Why?
|
| Mental Status Schedule | 4 | 2017 | 24 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2013 | 398 | 0.090 |
Why?
|
| Drug Therapy, Combination | 3 | 2010 | 288 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 429 | 0.090 |
Why?
|
| Forecasting | 2 | 2003 | 142 | 0.090 |
Why?
|
| Reference Values | 4 | 2013 | 246 | 0.090 |
Why?
|
| Sample Size | 2 | 2020 | 38 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2015 | 766 | 0.080 |
Why?
|
| Osteoarthritis | 2 | 2003 | 79 | 0.080 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2009 | 54 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2009 | 124 | 0.080 |
Why?
|
| Pain | 2 | 2009 | 287 | 0.080 |
Why?
|
| Consensus | 2 | 2018 | 85 | 0.080 |
Why?
|
| Knee Joint | 1 | 2009 | 142 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2008 | 48 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 684 | 0.070 |
Why?
|
| Pennsylvania | 3 | 2012 | 82 | 0.070 |
Why?
|
| Primary Prevention | 2 | 2017 | 54 | 0.070 |
Why?
|
| Kidney | 1 | 2011 | 518 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 217 | 0.070 |
Why?
|
| Oxygen | 1 | 2008 | 142 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2020 | 3505 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 876 | 0.070 |
Why?
|
| Plant Preparations | 1 | 2006 | 27 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 1062 | 0.070 |
Why?
|
| Cholesterol, LDL | 2 | 2017 | 173 | 0.070 |
Why?
|
| Mental Recall | 1 | 2006 | 51 | 0.070 |
Why?
|
| Adipose Tissue | 3 | 2016 | 349 | 0.070 |
Why?
|
| Hyperparathyroidism | 1 | 2005 | 9 | 0.070 |
Why?
|
| Parathyroidectomy | 1 | 2005 | 21 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2005 | 49 | 0.060 |
Why?
|
| Health Behavior | 2 | 2006 | 236 | 0.060 |
Why?
|
| Muscle Weakness | 2 | 2011 | 37 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 28 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2004 | 69 | 0.060 |
Why?
|
| Confidence Intervals | 3 | 2017 | 149 | 0.060 |
Why?
|
| Vasodilation | 1 | 2004 | 94 | 0.060 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 35 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 873 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2005 | 137 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2014 | 220 | 0.060 |
Why?
|
| Pedigree | 2 | 2016 | 140 | 0.060 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 363 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2011 | 765 | 0.060 |
Why?
|
| Albumins | 2 | 2014 | 45 | 0.050 |
Why?
|
| Marriage | 1 | 2003 | 6 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2003 | 25 | 0.050 |
Why?
|
| Health Services Needs and Demand | 2 | 2020 | 81 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2014 | 61 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2012 | 20 | 0.050 |
Why?
|
| Systole | 3 | 2014 | 99 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 68 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 99 | 0.050 |
Why?
|
| Demography | 2 | 2016 | 110 | 0.050 |
Why?
|
| Probability | 2 | 2004 | 159 | 0.050 |
Why?
|
| Tennessee | 2 | 2012 | 102 | 0.050 |
Why?
|
| Reserpine | 1 | 2001 | 3 | 0.050 |
Why?
|
| Atenolol | 1 | 2001 | 6 | 0.050 |
Why?
|
| Muscles | 1 | 2002 | 62 | 0.050 |
Why?
|
| Weight-Bearing | 2 | 2013 | 40 | 0.050 |
Why?
|
| Laryngoscopes | 2 | 2011 | 12 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2017 | 191 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 297 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2012 | 354 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 28 | 0.050 |
Why?
|
| Polypharmacy | 1 | 2020 | 17 | 0.050 |
Why?
|
| Diet | 1 | 2003 | 390 | 0.050 |
Why?
|
| Captopril | 1 | 2000 | 8 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2020 | 26 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2001 | 75 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 63 | 0.040 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 2 | 2014 | 10 | 0.040 |
Why?
|
| Food Supply | 1 | 2001 | 67 | 0.040 |
Why?
|
| Poverty | 1 | 2001 | 115 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 629 | 0.040 |
Why?
|
| Drinking Behavior | 1 | 2019 | 10 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2009 | 30 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2004 | 512 | 0.040 |
Why?
|
| Video Recording | 1 | 2019 | 59 | 0.040 |
Why?
|
| Angina Pectoris | 1 | 1999 | 22 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 97 | 0.040 |
Why?
|
| Random Allocation | 2 | 2015 | 227 | 0.040 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2009 | 27 | 0.040 |
Why?
|
| Life Tables | 1 | 1998 | 5 | 0.040 |
Why?
|
| Verbal Behavior | 1 | 1998 | 9 | 0.040 |
Why?
|
| Judgment | 1 | 1998 | 11 | 0.040 |
Why?
|
| Body Height | 1 | 1998 | 34 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2017 | 40 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 12 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2017 | 27 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2019 | 156 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 107 | 0.040 |
Why?
|
| Mass Screening | 1 | 2019 | 263 | 0.040 |
Why?
|
| Age Distribution | 1 | 2017 | 206 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 160 | 0.040 |
Why?
|
| Carbon Radioisotopes | 1 | 2017 | 24 | 0.040 |
Why?
|
| Visual Perception | 1 | 1998 | 116 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 59 | 0.030 |
Why?
|
| North America | 1 | 2016 | 32 | 0.030 |
Why?
|
| Epidemiologic Studies | 2 | 2010 | 20 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2016 | 90 | 0.030 |
Why?
|
| Minisatellite Repeats | 1 | 2016 | 9 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2016 | 84 | 0.030 |
Why?
|
| Body Weight | 1 | 1998 | 309 | 0.030 |
Why?
|
| Physical Examination | 1 | 2016 | 92 | 0.030 |
Why?
|
| Muscle Stretching Exercises | 1 | 2015 | 6 | 0.030 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2015 | 17 | 0.030 |
Why?
|
| Mental Health | 1 | 2016 | 119 | 0.030 |
Why?
|
| Postural Balance | 1 | 2017 | 182 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2015 | 77 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 186 | 0.030 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2016 | 97 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2015 | 57 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 93 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 163 | 0.030 |
Why?
|
| Stroop Test | 1 | 2014 | 5 | 0.030 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2014 | 12 | 0.030 |
Why?
|
| Propensity Score | 1 | 2014 | 39 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 97 | 0.030 |
Why?
|
| Receptor, EphA1 | 1 | 2013 | 2 | 0.030 |
Why?
|
| Macaca fascicularis | 1 | 2015 | 434 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2015 | 249 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2008 | 895 | 0.030 |
Why?
|
| Educational Status | 1 | 2014 | 181 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2014 | 115 | 0.030 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 60 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2014 | 117 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 16 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2014 | 178 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 112 | 0.030 |
Why?
|
| Homeostasis | 1 | 2013 | 132 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 63 | 0.030 |
Why?
|
| Phenotype | 1 | 2014 | 632 | 0.030 |
Why?
|
| Nerve Net | 1 | 2014 | 123 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2013 | 125 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2013 | 246 | 0.030 |
Why?
|
| Age of Onset | 1 | 2012 | 94 | 0.030 |
Why?
|
| Urban Population | 1 | 2012 | 89 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2012 | 45 | 0.030 |
Why?
|
| Esophageal Motility Disorders | 1 | 2011 | 6 | 0.030 |
Why?
|
| Viscosity | 1 | 2011 | 21 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2011 | 11 | 0.020 |
Why?
|
| Food | 1 | 2011 | 43 | 0.020 |
Why?
|
| Cystatin C | 1 | 2011 | 31 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 917 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2011 | 70 | 0.020 |
Why?
|
| Animals | 2 | 2015 | 7510 | 0.020 |
Why?
|
| Milk | 1 | 2010 | 16 | 0.020 |
Why?
|
| Pressure | 1 | 2010 | 51 | 0.020 |
Why?
|
| Water | 1 | 2010 | 56 | 0.020 |
Why?
|
| Mathematics | 1 | 2010 | 9 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 171 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 271 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 529 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2010 | 102 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2009 | 48 | 0.020 |
Why?
|
| Psychological Tests | 1 | 2009 | 35 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 104 | 0.020 |
Why?
|
| Adolescent | 2 | 2007 | 3568 | 0.020 |
Why?
|
| Length of Stay | 2 | 2003 | 312 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2009 | 199 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2010 | 476 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2008 | 77 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 581 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2008 | 78 | 0.020 |
Why?
|
| Canada | 1 | 2007 | 56 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 2665 | 0.020 |
Why?
|
| Dementia, Vascular | 1 | 2006 | 12 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2006 | 45 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2005 | 97 | 0.020 |
Why?
|
| Psychotropic Drugs | 1 | 2005 | 12 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2005 | 12 | 0.020 |
Why?
|
| Psychology | 1 | 2005 | 24 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2005 | 114 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2005 | 138 | 0.020 |
Why?
|
| Benzothiadiazines | 1 | 2004 | 2 | 0.010 |
Why?
|
| Emotions | 1 | 2005 | 58 | 0.010 |
Why?
|
| Italy | 1 | 2003 | 15 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2003 | 147 | 0.010 |
Why?
|
| Muscular Atrophy | 1 | 2002 | 71 | 0.010 |
Why?
|
| Nutrition Disorders | 1 | 2001 | 12 | 0.010 |
Why?
|
| Baltimore | 1 | 2001 | 50 | 0.010 |
Why?
|
| Diastole | 1 | 2000 | 96 | 0.010 |
Why?
|
| Epidemiologic Research Design | 1 | 1999 | 5 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 1999 | 28 | 0.010 |
Why?
|
| Models, Statistical | 1 | 1999 | 175 | 0.010 |
Why?
|
| Torque | 1 | 1998 | 20 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 1998 | 23 | 0.010 |
Why?
|
| Maryland | 1 | 1998 | 28 | 0.010 |
Why?
|
| Social Perception | 1 | 1998 | 24 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 1998 | 187 | 0.010 |
Why?
|
| Morbidity | 1 | 1996 | 98 | 0.010 |
Why?
|